Compare Citius Pharmaceuticals Inc (CTXR) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.21 (market cap $17.89B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is far larger — about 1313.5× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 44,866,592). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and iShares iBoxx $ High Yield Corporate Bond ETF for 59 Days on average.
| CTXR | HYG | |
|---|---|---|
Market Cap | $13.62M | $17.89B |
Volume | 132,438 | 44,866,592 |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $81.28 |
52-Week Low | $0.48 | $76.90 |
Typical Hold Time | 16 Days | 59 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
HYG (iShares iBoxx $ High Yield Corporate Bond ETF) trades at $77.115, down 0.08% with a bearish technical signal from moving averages. The fund has shown unusual options activity recently amid a challenging bond market environment where Treasury yields have reached multi-year highs. Recent dividend payments of $0.34-$0.44 per share provide income support, but the overall technical picture remains weak with significant selling pressure.
The outlook for HYG remains challenged by rising interest rates and bond market volatility. While the fund offers attractive yield income through regular dividends, the bearish technical momentum and elevated Treasury yields create headwinds for price appreciation. Key risks include further rate hikes and credit spread widening in the high-yield bond market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
